Completed NA INTERVENTIONAL 2-arm NCT01149642

Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer (IMPATOX)

Phase III Multicenter, Randomised and Double-blind Study Comparing an Oral Immunomodulatory Solution Versus a Placebo in Preventing Severe Acute Mucositis in Head and Neck Cancer Patients Treated Surgically and Concomitantly With Radiochemotherapy

Sponsor: GORTEC

Conditions Head and Neck Cancer Severe Acute Mucositis

Interventions Oral Impact Placebo

Updated 6 times since 2017 Last updated: Aug 11, 2020 Started: Nov 30, 2009 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Head and Neck Cancer and Severe Acute Mucositis and is currently completed. GORTEC leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Sep 2020 — Jan 2021 [monthly]

Completed NA

Phase: PHASE3 → NA
Jun 2018 — Sep 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GORTEC
Institut du Cancer de Montpellier - Val d'Aurelle

Data source: Institut du Cancer de Montpellier - Val d'Aurelle

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France